Head-to-head evidence
exendin-4 Fc fusion (JY09) vs Supaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
exendin-4 Fc fusion (JY09)
Developed by Beijing Dongfang Biotech
NCT06247748 · Phase 1 · completed
Every participant received the same open-label treatment with no control group, and the study measured drug-interaction and pharmacokinetic markers rather than a clinical benefit. No results have been posted.
Supaglutide
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT04998032 · Phase 2/3 · completed
In this randomized, double-blind, placebo-controlled Phase 2b/3 trial in 620 adults with type 2 diabetes already taking metformin, adding once-weekly supaglutide significantly lowered blood-sugar control (HbA1c) at 24 weeks compared with adding placebo, with a clearly significant treatment difference.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: exendin-4 Fc fusion (JY09)'s landscape · Supaglutide's landscape